Mirati Therapeutics Inc(MRTX) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Current Price

$144.00

RSI

20.395

Beta:

1.471042

February 25, 2021
41.9M
-77.9M

224.715 %
-6.874 %
-39.669 %
-43.086 %

$13,398,000
$3,335,000
$12,926,000
$0
$0
$0
301.739 %
-287.586 %
100.000 %
%
0.000 %

$-357,937,000
$-213,256,000
$-98,418,000
$-70,430,000
$-83,118,000
$-64,544,000
-40.421 %
-53.850 %
-28.438 %
18.015 %
-22.347 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.